The 5-Second Trick For Imipenem
MI-CP151 was a section 1b randomised, double-blind, placebo controlled, dose-escalation, multicentre research To guage numerous intravenous doses of sifalimumab, in Grownup clients with dermatomyositis or polymyositis (NCT00533091). Main demo targets have been To guage the security and tolerability of sifalimumab in dermatomyositis or polymyositis